United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Horny goat weed is an extract from the epimedium grandiflorum plant, a flowering shrub native to Asia, Africa, and parts of ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in ...

The phosphodiesterase 5 inhibitor mirodenafil, a drug from the Viagra family, could have beneficial effects on cognition ...

The ability to characterize the pulmonary circulation more fully paved the way for many advances. In the 1950s, Dr David ...

The results of the Mont Blanc trial were announced in October 2022. The second Phase 3 trial of NCX 470, Denali, is ongoing ...

Prostate cancer occurs when abnormal cells grow and multiply in the prostate gland This condition can have a significant ...

Sumitomo Mitsui Trust Group Inc. lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 0.4% during the 3rd quarter, according to its most recent filing with the Securities ...

an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the ...